Name: Atovaquone
Brand: Selleck Chemicals
SKU: S3079
Availability: InStock
Rating: 5 (9 reviews)

Jump to

Quality Control

Batch: Purity: 99.93%

99.93

Related Targets	Integrase Bacterial Antibiotics Anti-infection Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease
Other Fungal Inhibitors	Cycloheximide Tolnaftate Manogepix (E1210) Amorolfine HCl Thimerosal Isavuconazole Neticonazole Allicin Neticonazole Hydrochloride Juglone

Solubility

In vitro
Batch:

DMSO : 11 mg/mL (29.98 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.500mg/ml (1.36mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	366.84	Formula	C₂₂H₁₉ClO₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	95233-18-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Atavaquone			Smiles	C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O

Mechanism of Action

In vitro	Atovaquone (atavaquone) is a chemical compound that belongs to the class of naphthalenes. This compound is a hydroxy-1,4-naphthoquinone, an analog of ubiquinone, with antipneumocystic activity. It is an anti-protozoal mitochondrial electron transport inhibitor; Antimalarial; Antipneumocystic, and has also been used to treat toxoplasmosis. This chemical acts by inhibiting the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket.
In vivo	Atovaquone is a unique naphthoquinone with broad-spectrum antiprotozoal activity. It is effective for the treatment and prevention of Pneumocystis carinii pneumonia (PCP), this compound is effective in combination with proguanil for the treatment and prevention of malaria, and it is effective in combination with azithromycin for the treatment of babesiosis.
References	[1] https://pubmed.ncbi.nlm.nih.gov/8651372/ [2] https://pubmed.ncbi.nlm.nih.gov/12791689/ [3] http://www.ncbi.nlm.nih.gov/pmc/articles/PMC127192/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05458752	Completed	Pneumocystis Jirovecii Infection	Central Hospital Nancy France	April 1 2020	--
NCT04002687	Completed	Malaria	Medicines for Malaria Venture\|Richmond Pharmacology Limited	April 4 2019	Phase 1
NCT02628080	Completed	Carcinoma Non-Small-Cell Lung	University of Oxford	May 2016	Early Phase 1
NCT01858831	Completed	Malaria	GlaxoSmithKline	April 2012	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Atovaquone Fungal inhibitor

Chemical Structure

Molecular Weight: 366.84